Annual EBIT
-$542.46 M
+$116.25 M+17.65%
December 31, 2023
Summary
- As of February 7, 2025, RARE annual earnings before interest & taxes is -$542.46 million, with the most recent change of +$116.25 million (+17.65%) on December 31, 2023.
- During the last 3 years, RARE annual EBIT has fallen by -$390.39 million (-256.72%).
- RARE annual EBIT is now -8145.33% below its all-time high of -$6.58 million, reached on December 31, 2011.
Performance
RARE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$117.50 M
-$2.72 M-2.37%
September 30, 2024
Summary
- As of February 7, 2025, RARE quarterly earnings before interest & taxes is -$117.50 million, with the most recent change of -$2.72 million (-2.37%) on September 30, 2024.
- Over the past year, RARE quarterly EBIT has increased by +$23.83 million (+16.86%).
- RARE quarterly EBIT is now -239.99% below its all-time high of $83.94 million, reached on December 31, 2018.
Performance
RARE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$496.23 M
+$23.83 M+4.58%
September 30, 2024
Summary
- As of February 7, 2025, RARE TTM earnings before interest & taxes is -$496.23 million, with the most recent change of +$23.83 million (+4.58%) on September 30, 2024.
- Over the past year, RARE TTM EBIT has increased by +$74.08 million (+12.99%).
- RARE TTM EBIT is now -10732.29% below its all-time high of -$4.58 million, reached on December 31, 2012.
Performance
RARE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RARE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.6% | +16.9% | +13.0% |
| 3 y3 years | -256.7% | -83.2% | -54.8% |
| 5 y5 years | -175.2% | -4.3% | -24.6% |
RARE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -28.1% | +17.6% | -7.2% | +47.6% | -17.2% | +25.0% |
| 5 y | 5-year | -256.7% | +17.6% | -444.0% | +47.6% | -226.3% | +25.0% |
| alltime | all time | -8145.3% | +17.6% | -240.0% | +47.6% | <-9999.0% | +25.0% |
Ultragenyx Pharmaceutical EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$117.50 M(+2.4%) | -$496.23 M(-4.6%) |
| Jun 2024 | - | -$114.78 M(-25.7%) | -$520.06 M(-5.3%) |
| Mar 2024 | - | -$154.38 M(+40.9%) | -$549.00 M(+1.2%) |
| Dec 2023 | -$542.46 M(-17.6%) | -$109.56 M(-22.5%) | -$542.46 M(-4.9%) |
| Sep 2023 | - | -$141.33 M(-1.7%) | -$570.31 M(-12.7%) |
| Jun 2023 | - | -$143.72 M(-2.8%) | -$653.29 M(-1.2%) |
| Mar 2023 | - | -$147.84 M(+7.6%) | -$661.37 M(+0.4%) |
| Dec 2022 | -$658.71 M(+55.5%) | -$137.41 M(-38.7%) | -$658.71 M(+2.9%) |
| Sep 2022 | - | -$224.31 M(+47.8%) | -$639.93 M(+33.4%) |
| Jun 2022 | - | -$151.81 M(+4.6%) | -$479.75 M(+8.7%) |
| Mar 2022 | - | -$145.18 M(+22.4%) | -$441.39 M(+4.2%) |
| Dec 2021 | -$423.56 M(+178.5%) | -$118.63 M(+85.0%) | -$423.56 M(+32.1%) |
| Sep 2021 | - | -$64.13 M(-43.5%) | -$320.67 M(+1.3%) |
| Jun 2021 | - | -$113.45 M(-10.9%) | -$316.49 M(+87.4%) |
| Mar 2021 | - | -$127.34 M(+708.9%) | -$168.88 M(+11.1%) |
| Dec 2020 | -$152.07 M(-61.8%) | -$15.74 M(-73.7%) | -$152.07 M(-32.8%) |
| Sep 2020 | - | -$59.95 M(-275.5%) | -$226.43 M(-18.9%) |
| Jun 2020 | - | $34.16 M(-130.9%) | -$279.19 M(-32.3%) |
| Mar 2020 | - | -$110.53 M(+22.7%) | -$412.30 M(+3.5%) |
| Dec 2019 | -$398.31 M(+102.1%) | -$90.11 M(-20.0%) | -$398.31 M(+77.6%) |
| Sep 2019 | - | -$112.70 M(+13.9%) | -$224.26 M(+11.5%) |
| Jun 2019 | - | -$98.96 M(+2.5%) | -$201.21 M(+2.1%) |
| Mar 2019 | - | -$96.54 M(-215.0%) | -$197.15 M(+0.0%) |
| Dec 2018 | -$197.10 M | $83.94 M(-193.6%) | -$197.10 M(-46.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$89.65 M(-5.5%) | -$367.26 M(+1.6%) |
| Jun 2018 | - | -$94.90 M(-1.6%) | -$361.33 M(+4.8%) |
| Mar 2018 | - | -$96.49 M(+11.9%) | -$344.87 M(+8.3%) |
| Dec 2017 | -$318.34 M(+28.4%) | -$86.23 M(+3.0%) | -$318.34 M(+5.2%) |
| Sep 2017 | - | -$83.71 M(+6.7%) | -$302.66 M(+6.3%) |
| Jun 2017 | - | -$78.44 M(+12.1%) | -$284.73 M(+7.7%) |
| Mar 2017 | - | -$69.95 M(-0.8%) | -$264.34 M(+6.6%) |
| Dec 2016 | -$248.01 M(+67.9%) | -$70.55 M(+7.2%) | -$248.01 M(+6.2%) |
| Sep 2016 | - | -$65.78 M(+13.3%) | -$233.62 M(+12.4%) |
| Jun 2016 | - | -$58.05 M(+8.3%) | -$207.77 M(+15.5%) |
| Mar 2016 | - | -$53.62 M(-4.5%) | -$179.86 M(+21.7%) |
| Dec 2015 | -$147.74 M(+160.2%) | -$56.16 M(+40.6%) | -$147.74 M(+36.1%) |
| Sep 2015 | - | -$39.94 M(+32.5%) | -$108.52 M(+28.5%) |
| Jun 2015 | - | -$30.14 M(+40.2%) | -$84.42 M(+24.3%) |
| Mar 2015 | - | -$21.50 M(+26.9%) | -$67.94 M(+19.7%) |
| Dec 2014 | -$56.78 M(+75.9%) | -$16.94 M(+7.0%) | -$56.78 M(+15.0%) |
| Sep 2014 | - | -$15.84 M(+15.9%) | -$49.36 M(+19.6%) |
| Jun 2014 | - | -$13.66 M(+32.1%) | -$41.29 M(+15.1%) |
| Mar 2014 | - | -$10.34 M(+8.5%) | -$35.87 M(+11.1%) |
| Dec 2013 | -$32.28 M(+101.9%) | -$9.53 M(+22.7%) | -$32.28 M(+18.1%) |
| Sep 2013 | - | -$7.76 M(-5.9%) | -$27.34 M(+39.6%) |
| Jun 2013 | - | -$8.25 M(+22.2%) | -$19.57 M(+72.8%) |
| Mar 2013 | - | -$6.75 M(+47.3%) | -$11.33 M(+147.3%) |
| Dec 2012 | -$15.98 M(+143.0%) | -$4.58 M | -$4.58 M |
| Dec 2011 | -$6.58 M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical annual earnings before interest & taxes?
- What is the all time high annual EBIT for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM EBIT year-on-year change?
What is Ultragenyx Pharmaceutical annual earnings before interest & taxes?
The current annual EBIT of RARE is -$542.46 M
What is the all time high annual EBIT for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual earnings before interest & taxes is -$6.58 M
What is Ultragenyx Pharmaceutical annual EBIT year-on-year change?
Over the past year, RARE annual earnings before interest & taxes has changed by +$116.25 M (+17.65%)
What is Ultragenyx Pharmaceutical quarterly earnings before interest & taxes?
The current quarterly EBIT of RARE is -$117.50 M
What is the all time high quarterly EBIT for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly earnings before interest & taxes is $83.94 M
What is Ultragenyx Pharmaceutical quarterly EBIT year-on-year change?
Over the past year, RARE quarterly earnings before interest & taxes has changed by +$23.83 M (+16.86%)
What is Ultragenyx Pharmaceutical TTM earnings before interest & taxes?
The current TTM EBIT of RARE is -$496.23 M
What is the all time high TTM EBIT for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM earnings before interest & taxes is -$4.58 M
What is Ultragenyx Pharmaceutical TTM EBIT year-on-year change?
Over the past year, RARE TTM earnings before interest & taxes has changed by +$74.08 M (+12.99%)